Almost half of the surveyed urologists View Approval of Provenge as a breakthrough in the treatment of prostateDecision Resources, one of the world ‘s leading research and advisory firm for pharmaceutical and healthcare issues, states that see nearly half of the surveyed urologists the approval of the Dendreon Provenge as a breakthrough in the treatment of prostate cancer, compared with 31 % of the surveyed oncologists. However, the agent writes oncologists likely than urologists.

Once approved last year by the U.S. Food and Drug Administration for asymptomatic and minimally symptomatic MCRPC Provenge is the first therapeutic cancer vaccine available in a cancer indication in a major pharmaceutical market.Reference: Schifferstein HNJ et al ambient ambient scent the night life User Chemosensory Perception; Issue the tenth?

.

Other Posts From Category "medicine":

Related Posts